Efficiency of GliSODi
Not Applicable
- Conditions
- ocomotive syndrome
- Registration Number
- JPRN-jRCTs031180310
- Lead Sponsor
- Koike Masato
- Brief Summary
Oral administration of GliSODin improved subjective symptoms, decreased TNFa, increased ucOC, and decreased body fat percentage in patients with locomotive syndrome, we found that GliSODin was effective in preventing and improving locomotive syndrome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 46
Inclusion Criteria
Volunteer with low back or knee pain and gait instability caused by motor weakness
Exclusion Criteria
Volunteer with diseases including internal medicine, psychogenic disorders, neuromuscular diseases, postoperative state of orthopaedic surgery, allergy against wheat and melon
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Questionnaires on subjective symptoms (Health-related QOL SF-36, Japanese Orthopedic Surgery Association Low Back Pain Disease Questionnaire (JOABPEQ), Functional Assessment Scale for Osteoarthritis Patients (JKOM), Locomo 25 (Activity Evaluation Indicator), Motor Function (Grip strength, coordination function evaluation, walking speed), Chalder Fatigue Scale
- Secondary Outcome Measures
Name Time Method Presence or absence of side effects due to long-term oral administration: Liver function (AST, ALT), Renal function (BUN, Cr)<br>Oxidative stress markers (blood oxidative stress level dROMs, blood antioxidant power BAP, blood SOD activity), Whole body DEXA (muscle mass, fat mass), Bone density bone formation marker P1NP, Bone resorption marker TRACP 5b, X-ray of knee joint and lumbar spine)